CN108699135B - 用于改善病毒载体效率的组合物和方法 - Google Patents

用于改善病毒载体效率的组合物和方法 Download PDF

Info

Publication number
CN108699135B
CN108699135B CN201680070996.0A CN201680070996A CN108699135B CN 108699135 B CN108699135 B CN 108699135B CN 201680070996 A CN201680070996 A CN 201680070996A CN 108699135 B CN108699135 B CN 108699135B
Authority
CN
China
Prior art keywords
leu
peptide
ala
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680070996.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699135A (zh
Inventor
萨利哈·玛耶杜尔
大卫·费纳尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evry Wald Esson University
Institut National de la Sante et de la Recherche Medicale INSERM
Genethon
Original Assignee
Evry Wald Esson University
Institut National de la Sante et de la Recherche Medicale INSERM
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evry Wald Esson University, Institut National de la Sante et de la Recherche Medicale INSERM, Genethon filed Critical Evry Wald Esson University
Publication of CN108699135A publication Critical patent/CN108699135A/zh
Application granted granted Critical
Publication of CN108699135B publication Critical patent/CN108699135B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680070996.0A 2015-12-03 2016-11-30 用于改善病毒载体效率的组合物和方法 Expired - Fee Related CN108699135B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15306924.0 2015-12-03
EP15306924 2015-12-03
EP16194180 2016-10-17
EP16194180.2 2016-10-17
PCT/EP2016/079304 WO2017093330A1 (en) 2015-12-03 2016-11-30 Compositions and methods for improving viral vector efficiency

Publications (2)

Publication Number Publication Date
CN108699135A CN108699135A (zh) 2018-10-23
CN108699135B true CN108699135B (zh) 2022-10-04

Family

ID=57485463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680070996.0A Expired - Fee Related CN108699135B (zh) 2015-12-03 2016-11-30 用于改善病毒载体效率的组合物和方法

Country Status (6)

Country Link
US (2) US11371061B2 (https=)
EP (1) EP3383896A1 (https=)
JP (2) JP7350485B2 (https=)
CN (1) CN108699135B (https=)
CA (1) CA3004971A1 (https=)
WO (1) WO2017093330A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080799B (zh) * 2011-06-30 2021-03-12 吉尼松公司 具有病毒感染增强性质的肽及其用途
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
EP3665285A4 (en) * 2017-08-10 2021-08-11 Aadigen, LLC PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR VIRUS ADMINISTRATION
CN107686523B (zh) * 2017-09-15 2021-05-14 山西大学 一种肿瘤酸度响应自噬诱导多肽及其制备方法和应用
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220280602A1 (en) * 2019-07-31 2022-09-08 Lemonex Inc. Anticancer agent and method for preparation of porous silica particle
US20240025959A1 (en) * 2020-08-24 2024-01-25 University Of Southern California Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
MX2023009554A (es) * 2021-02-15 2023-09-13 Biomarin Pharm Inc Uso de peptidos ricos en histidina como reactivo de transfeccion para la produccion de raav y rbv.
CN113713082B (zh) * 2021-08-27 2023-07-18 福建医科大学 一种用于阿尔茨海默症的纳米自噬诱导剂及其制备方法与应用
CN114316065B (zh) * 2021-10-29 2023-09-22 新乡医学院 小分子肽及其应用、细胞培养基、核酸分子
WO2024243639A1 (en) * 2023-05-31 2024-12-05 The Florey Institute Of Neuroscience And Mental Health Autophagy-inducing peptides
WO2025179154A1 (en) * 2024-02-21 2025-08-28 Vycellix, Inc. Compositions and methods for enhancing transduction efficiency of viral vectors with heparin and analogues thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106684A2 (en) * 2010-02-25 2011-09-01 San Diego State University Foundation Compositions and methods for modulating autophagy
WO2013119377A1 (en) * 2012-02-11 2013-08-15 Board Of Regents, The University Of Texas System Autophagy-inducing peptide
CN104080799A (zh) * 2011-06-30 2014-10-01 吉尼松公司 具有病毒感染增强性质的肽及其用途
WO2015042272A1 (en) * 2013-09-18 2015-03-26 Ndsu Research Foundation COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH γ-HERPESVIRUSES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US20150352228A1 (en) 2013-01-11 2015-12-10 Bruce TORBET Methods and compositions for enhancing transduction efficiency of retroviral vectors
US20140271584A1 (en) 2013-03-15 2014-09-18 The Research Foundation For The State University Of New York Methods and Compositions for Direct Reprogramming of Somatic Cells to Stem Cells, and Uses of these Cells
WO2016119856A1 (en) 2015-01-29 2016-08-04 Universite De Strasbourg Autophagy-inducing molecules for increasing insulin release
EP3141680B1 (en) * 2015-09-09 2018-01-31 U-Shin Italia S.p.A. Electronic handle for a vehicle door
CN108431033A (zh) * 2015-09-28 2018-08-21 泰莱托恩基金会 骨生长病症的治疗
US10993983B2 (en) * 2016-03-18 2021-05-04 Trustees Of Tufts College Cyclic peptide epitopes and small-molecule mimics for inducing autophagy
WO2018013568A1 (en) * 2016-07-11 2018-01-18 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
TW201910511A (zh) * 2017-05-30 2019-03-16 美商維泰克斯製藥公司 C3融合蛋白以及其製備及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106684A2 (en) * 2010-02-25 2011-09-01 San Diego State University Foundation Compositions and methods for modulating autophagy
CN104080799A (zh) * 2011-06-30 2014-10-01 吉尼松公司 具有病毒感染增强性质的肽及其用途
WO2013119377A1 (en) * 2012-02-11 2013-08-15 Board Of Regents, The University Of Texas System Autophagy-inducing peptide
WO2015042272A1 (en) * 2013-09-18 2015-03-26 Ndsu Research Foundation COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH γ-HERPESVIRUSES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism;He C,等;《Cell》;20130829;第154卷(第5期);第1085-1099页 *
Common and divergent functions of Beclin 1 and Beclin 2;Galluzzi L,等;《Cell Res》;20131231;第23卷(第12期);第一段 *
Identification of a candidate therapeutic autophagy-inducing peptide;Shoji-Kawata S 等;《Nature》;20120214;第94卷(第7436期);摘要 *
Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance the entry of lentiviral vectors into human cells;Majdoul Saliha等;《JOURNAL OF BIOLOGICAL CHEMISTRY》;20171110;第292卷(第45期);第18672-18681页 *

Also Published As

Publication number Publication date
JP2019501882A (ja) 2019-01-24
JP7350485B2 (ja) 2023-09-26
CN108699135A (zh) 2018-10-23
US20230117384A1 (en) 2023-04-20
CA3004971A1 (en) 2017-06-08
US20180318447A1 (en) 2018-11-08
JP2022002530A (ja) 2022-01-11
US11371061B2 (en) 2022-06-28
WO2017093330A1 (en) 2017-06-08
EP3383896A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CN108699135B (zh) 用于改善病毒载体效率的组合物和方法
AU2019325332B2 (en) Compositions and methods for modulating transduction efficiency of adeno-associated viruses
KR20200083550A (ko) ACE-tRNA에 의한 유전자 재지정을 통해 정지 코돈을 구조하는 방법
US20220169993A1 (en) Destabilising domains for conditionally stabilising a protein
CN104080799B (zh) 具有病毒感染增强性质的肽及其用途
US7135339B2 (en) Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
Han et al. Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery
WO2023083224A1 (en) The construction of a new virus vector packaging cell line of high productivity
EP2643343A1 (en) Identification of a human gyrovirus and applications.
Chinnasamy et al. Production of multicistronic HIV-1 based lentiviral vectors
EP1660665A2 (en) Chimaeric vector system
US20250304996A1 (en) Pseudotyped lentiviral vectors
US20230416307A1 (en) Engineered cyclic peptides for enhancing viral production
WO2025024460A2 (en) Methods and compositions for modulating aav infection
CN110054678B (zh) 一种膜结合型mFLT3LG蛋白及其应用
US20100029568A1 (en) Tighter-binding c-peptide inhibitors of hiv-1 entry
WO2025231397A1 (en) Modified hek cell lines for improved aav production
EP4704813A2 (en) Cellular delivery of therapeutics using fusogenic vesicles
Chen Factors affecting the production of pantropic retroviral and lentiviral vectors
Shen et al. Identification of the membrane-spanning domain of glycoprotein 45 in bovine immunodeficiency virus.
WO2019097290A1 (en) Enhancement of biologics production in cell culture systems by fertilin-derived peptides
Hoop Modulation of the transduction of pseudotyped lentiviral vectors and their application for the production of recombinant proteins
Costa New cell lines for the manufacture of lentivirus
Chu Surface Remodeling of Lentiviral and Adeno-Associated Viral Vectors via Metabolically Introduced Bioorthogonal Functionalities

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20221004

CF01 Termination of patent right due to non-payment of annual fee